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Orthotopic Liver Transplantation in Dogs 
Receiving FK-506 
S. Todo. L. Podesta. P. ChapChap. D. Kahn. C-E. Pan. Y. Ueda. K. Okuda. O. Imventarza. 
A. Casavilla. A.J. Demetris. L. Makowka. and T.E. Starzl 
r has long been assumed. and for good 
reasons. that information about immuno-
suppressIOn obtained with a specific organ 
should be applicable for all kinds of grafts. I 
The drug FK-506 (FK). which was developed 
by scientists at the Fujisawa Pharmaceutical 
Co. Ltd. Osaka. Japan. has permitted the 
successfui transplantation of heterotopic 
hearts in rats2•3 and kidneys in dogs:D~ Infor-
mation on liver transplantation using FK has 
been limited to preliminary observations in 
dogs with a maximum follow-up of I monthK~ 
We report here an encouraging experience of 
liver transplantation in dogs. The results have 
been compared with those obtained with 
cyclosporinc (CyA) at an earlier time.6 
MATERIALS AND METHODS 
Fasted beagle or mongrel dOllS weighing 13 to 18 kg 
underwent orthotopic liver transplantation under anes-
thesia induced bv thiopental. 25 mg/kg. and maintained 
by pentobarbital. 2 mg/kg. ketamine and 0.1 mg/kg 
pancuronium. Venovenous bypass was routinely used.' 
Orthotopic liver transplantation in dogs is a difficult 
procedure. with such a high operative and perioperative 
mortality that discriminating drug studies can be done 
only with culled "good" experiments. Thus. as in past 
reports.' survival for at least six days was a condition 
imposed for inclUSion in the definillve series. Twenty· 
three transplantallons were required to obtain ten defini-
tive experiments, All 13 discarded recIpients died during 
or within 48 hours of operallon from technical complica-
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tion not ascribable to immunosuppression. and most of 
the discarded animals never were given FK. 
One gram cephalosporin was given intravenously dur-
ing the operation and intramuscularly for the next three 
days. Two milligrams atropine sulphate was given intra-
venously during the operation. twice a day intramuscu· 
larly for the first week. and once a day for the second 
week to prevent or minimize vomiting and consequent 
Intussusception. The daily intramuscular atropine dose 
was reduced to I mg during the third week. 
The beagles were unrelated animals but from the same 
large colony. In the ten definitive experiments. the strain 
combinations were beagle donor to beagle recipient (B-B\ 
In the first five and mongrel donor to beagle recipient 
(M-B) in the second five. The results were not different In 
the two subgroups. and consequently. all analys~ were 
pooled, 
Blood samples were taken every three mornings for the 
measurement of levels of BUN. creatinine. SGOT. and 
total bilirubin (TBiI). A complete postmortem examina-
tion was performed immediately in animals that died. 
Tissues were fixed with formalin and stained with hema· 
toxylin and eosin. Histopathologic changes will be men-
tioned only brieHy because the only tissues were from the 
three ammals who died. 
A diet was started on the morning after the operation 
when the first dose of FK was given. The FK in powder 
form was placed in commercial capsules and given orally 
by digital placement in the oropharynx. The dose used 
was I mg/kg/d. After I month. the daily dose was 
reduced to 0.75 mg/kg. 
The results with FK were compared with those in 
untreated animals (6 B-B and 2 M-B) previously studied 
as part of an investigation of the CyA analogue NV A,,· A 
further comparison was made between the ten dog. 
treated with FK and nine dogs (four B-B and five M-B) 
treated previously with 20 mg/kg/d CyA for 30 days and 
15 mg/kg/d thereafter." 
RESULTS 
Survival 
The fate of the ten individual dogs is shown 
in Table I. Two dogs died after six and ten 
days because of intussusception and bile peri-
tonitis. respectively. There was no sign of 
rejection in either liver. A third animal whose 
liver function had slowly deteriorated died 
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Teble 1. ~ 8ncI c- crt Deeth After 0r1h0t0Pc 
liver q~ In Doge R-nring FK 
AnmIoI SonMI 
No. hI! c..oIo.th 
1 6 f~tion 
2 10 Biliary peritonitis 
3 30 Alive 
4 31 Alive 
5 32 NiNe 
6 36 Alive 
7 39 Alive 
8 44 Alive 
9 55 EtnICiItion. rejection 
10 80 Alive 
after 55 days; the last biiirubin level was 2.9 
mg/dL. At autopsy, there were no striking 
gross findings, but there were histopathologic 
findings of moderate rejection. 
The I-month liver survival rates shown in 
Fig I are compared with those in nontreated 
controls and those of nine dogs (four B-B and 
five M-B) treated with 20 mg/kg/d CyA. 
Graft Function 
The quality of liver graft function was 
uniformly good (Fig 2). The only animal 
whose bilirubin level rose to more than 2 
mg/dL was the dog that died of rejection and 
emaciation after 55 days. Secondary increases 
in SGOT levels after recovery from the imme-
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died. 
diate ischemic insult either were low grade or 
did not occur at all (Fig 2). 
The overall quality of liver function in the 
dogs treated with FK was better than that in 
the animals treated in our laboratory at an 
earlier time6 with CyA (Fig 2). The differ-
ences at I month were statistically significant 
(Table 2). 
Weight and WeI/-Being 
The only animal with serious emaciation 
was the B-B dog that died with moderate 
rejection after 55 days (Fig 3). This animal 
lost half of her body weight in 2 months. In 
comparison, the course of the longest survivor 
to date, now 65 days, is also shown (Fig 3). 
The latter dog lost 2.5 kg within the first 
postoperative week but has maintained the 
new weight with a good appetite since. He-
patic and renal functions have been com-
pletely normal in this dog. 
All seven of the survivors are clinically well 
from 35 to 65 days postoperatively. 
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Teble 2. SGOT and Till During Firet Month in Ten Dop Tr .. '" by FK and HiM Dop Tr .. '" by eyA 
........... 3d 7d 16d 24 d 30d 
SGOT(U/LI 
FK 47.2 % 29.6 83.1 :t 81.9 42.2:t 16.0 52.5 % 38.9 84.8:t 25.3 73.2 :t 50.1 
CvA 62.1 :t 70.7 152.2 :t 78.7 187.7 :t 165.7 132.3 :t 56.6 132.3 :t 56.6 111.2 :t: 65.3 
Pvlliue NS NS <.05 <.05 <.05 NS 
TBil (mg/cL) 
FK 0.2:t: 0 . ..1 0.3:t 0.2 0.3:t: 0.2 0.5:t: 4.0 0.7:t: 0.6 0.2 :t: 0.1 
eVA 0.2:t: 0.2 1.0 :t: 0.6 1.0:t 0.9 1.9:t 1.5 2.2:t 2.2 2.2:t: 1.0 
PVlllue NS <.05 <.05 
·CVA datil from expenmenta previouaIy reported.' 
DISCUSSION 
The similarities between FK and CyA are 
at least as remarkable as the differences. Both 
drugs are produced by soil bacteria. Both are 
lipophilic and hydrophobic, have incomplete 
absorption from the gastrointestinal tract. and 
act mainly by inhibition of interleukin 2 syn-
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thesis and/or binding. It would be incredible 
if drugs as powerful as these did not have 
major toxicity, and some of the reports at this 
symposium will feature the toxicity of FK in 
dogs. Whether the side effects are relatively 
species specific remains to be seen because 
rats tolerate the drug so well. 
In the meanwhile, the potency and potential 
value of FK has been evident even in the 
presumably unfavorable dog model. At this 
stage of postoperative evolution when seven of 
ten liver recipients are still alive 35 to 65 days 
postoperatively, this is the best crop of canine 
liver recipients ever produced in our labora-
tory over the last 30 years with single-drug 
therapy. 
In these experiments and in companion 
studies of renal transplantation in dogs,1 there 
has been little evidence that FK has intrinsic 
hepatotoxicity or nephrotoxicity. The freedom 
from renal damage is a stimulus for further 
development of FK because nephrotoxicity is 
the most limiting feature for the present-day 
use ofCyA. 
The experience with CyA has shown that 
the absence of nephrotoxicity in dogs does not 
ensure the same thing in humans. Neverthe-
less, the emergence of a drug as powerful as 
FK invites other possibilities than merely 
using it as a single drug. The use of FK in 
subtherapeutic and minimally toxic doses as a 
component of multiple-drug therapy has been 
a central theme with all of the in vivo and in 
vitro inquiries presented from the University 
of Pittsburgh workers at this meeting.7•IO 
LIVER TRANSPLANTATION IN DOGS UNDER FK-606 
SUMMARY 
Ten dogs that survived the perioperative 
events of liver transplantation were treated 
with I mg/kg/d oral FK. Eight of the recip-
ients lived for at least I month postopera-
tively. and seven are still alive with normal 
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hepatic function after 35 to 65 days. The 
consistency and good quality of results with 
this difficult transplant preparation using FK. 
in spite of its rumored great toxicity in dogs. 
have highlighted the importance of further 
developing the drug. 
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